Skip to main content
Livermore
Livermore
中文EN

BCIP Life Sciences Associates, LP's Form 4 filing

NewAmsterdam Pharma Co N.V. (NAMS) · filed Dec 17, 2024

Accession no.
0000950170-24-137335
Filed
Dec 17, 2024, 5:05 PM ET
Trade date
Dec 13, 2024
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 0 non-derivative transactions and 1 derivative transaction. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
BCIP Life Sciences Associates, LPCIK 000170292110% Owner
Bain Capital Life Sciences Investors, LLCCIK 000170303110% Owner
Bain Capital Life Sciences Fund II, L.P.CIK 000177318710% Owner
Bain Capital Life Sciences Investors II, LLCCIK 000179615510% Owner
BCLS II Investco, LPCIK 000181889310% Owner
BCLS II Investco (GP), LLCCIK 000181910110% Owner
Bain Capital Life Sciences Fund III, L.P.CIK 000187527310% Owner
BCLS Fund III Investments GP, LLCCIK 000195208010% Owner
Bain Capital Life Sciences III General Partner, LLCCIK 000195210610% Owner
BCLS Fund III Investments, LPCIK 000195210710% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

This filing has no transactions of this kind.

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 13, 2024Ordinary SharesPPurchaseAcquired+1,632,653$24.50+$39,999,835.231,632,653Indirect

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)